Dupixent (dupilumab) can cause joint pain because blocking certain immune signals involved in allergic inflammation appears to shift the immune system toward a different inflammatory pathway, one that targets joints, tendons, and the connective tissue where tendons attach to bone. This side effect is now formally recognized in the drug’s FDA prescribing information, and while it affects a relatively small percentage of patients, it can range from mild stiffness to pain severe enough to affect how you walk.
How Blocking Allergic Inflammation Can Trigger Joint Pain
Dupixent works by blocking two immune signaling molecules called IL-4 and IL-13, which drive the type of inflammation behind eczema, asthma, and nasal polyps. The problem is that these molecules also play a quieter role: they help keep other inflammatory pathways in check. IL-4, for instance, normally tamps down production of a different signal called IL-23. Lab studies on connective tissue cells at tendon-bone junctions have confirmed this relationship directly.
When Dupixent removes that brake, IL-23 activity can ramp up. IL-23, in turn, drives a type of inflammation closely associated with joint disease, particularly the kind seen in conditions like psoriatic arthritis and other forms of inflammatory arthropathy that target tendons and entheses (the spots where tendons and ligaments anchor into bone). In essence, suppressing one arm of the immune system can inadvertently unleash another. This isn’t a direct toxic effect of the drug on your joints. It’s an immune rebalancing act with unintended consequences.
How Common Is It?
In clinical trials, joint pain showed up at modestly higher rates in patients on Dupixent compared to placebo. Among patients treated for chronic rhinosinusitis with nasal polyps, 3% of those receiving Dupixent reported joint pain versus 2% on placebo. In eosinophilic esophagitis trials, the numbers were 2% versus 1%. These percentages are small, but they represent a real and consistent signal across multiple conditions the drug is used to treat.
The more serious form of this side effect, true inflammatory arthritis rather than simple joint aches, was first described in 2019 in three patients who developed the condition within 16 weeks of starting treatment. Since then, enough cases have accumulated through postmarketing reports that the FDA added a specific warning about joint pain to Dupixent’s label, noting that some cases resulted in hospitalization.
What the Joint Pain Feels Like
Dupixent-related joint symptoms don’t always look like typical arthritis. Patients generally develop some combination of three things: arthritis (inflammation within the joint itself), enthesitis (inflammation where tendons connect to bone, often felt at the heel, elbow, or knee), and tenosynovitis (inflammation of the sheath surrounding a tendon, causing swelling and pain with movement). You might feel it in one joint or several, and it can affect both large and small joints.
The timing varies widely. Some people notice joint symptoms within days of their first injection, while others don’t develop problems for months. The FDA label describes onset as “ranging from days to months after the first dose.” This unpredictable timeline can make it harder to connect the symptom to the medication, especially if you’ve been on Dupixent for a while before anything starts.
In more significant cases, patients have reported gait disturbances or decreased mobility. Standard rheumatologic blood tests often come back normal, meaning there are no autoimmune markers like rheumatoid factor to explain the inflammation. This pattern, called seronegative arthropathy, is consistent with the IL-23-driven mechanism described above rather than a traditional autoimmune arthritis.
What Happens if You Develop Joint Pain
The trajectory of Dupixent-related joint symptoms varies from person to person. Some patients find their symptoms resolve on their own even while continuing treatment. Others recover only after stopping the medication. The FDA label acknowledges both patterns, noting that “some patients’ symptoms resolved while continuing treatment” and “other patients recovered or were recovering following discontinuation.”
If you develop new or worsening joint pain while on Dupixent, a rheumatologic evaluation can help clarify whether the drug is the cause or whether something unrelated is going on. Because standard blood work for autoimmune conditions typically comes back negative in these cases, imaging like ultrasound may be more useful for identifying tendon or joint inflammation. Your prescriber will weigh whether the benefits of Dupixent for your primary condition outweigh the joint symptoms, and whether those symptoms are manageable or require stopping the drug.
Why This Side Effect Took Time to Recognize
Dupixent was approved in 2017, and the first reports of inflammatory arthritis didn’t appear until 2019. This lag is partly because the joint symptoms occur in a small subset of patients and partly because the connection isn’t obvious. Joint pain is common in the general population, and someone taking Dupixent for severe eczema or asthma might not immediately suspect their biologic injection is causing a sore knee or swollen finger. The seronegative nature of the arthritis, where standard lab tests look normal, also made it easier to dismiss early cases as coincidental.
The recognition that IL-4 suppression can unleash IL-23-driven joint inflammation has broader implications for how biologic medications are understood. Drugs that target one part of the immune system can have ripple effects on other pathways, and those effects sometimes only become clear once millions of patients have used a medication in the real world, outside the controlled setting of clinical trials.